Ovid Therapeutics Inc. is a US-based biopharmaceutical company striving to help patients and families suffering from neurological disorders. The company is currently developing several drugs, including OV101, OV329, OV350, OV882, and OV815, for the treatment of various neurological disorders, including fragile X syndrome, seizures, infantile spasms, angelman syndrome, and kinesin-family of proteins-associated neurological disorder. Ovid has partnered with various organizations and is headquartered in New York City.